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Mechanisms of molecular recognition in the pikromycin
polyketide synthase
Shuo Chen 1, Yongquan Xue 2, David H Sherman 2 and Kevin A Reynolds 1
Background: Modular polyketide synthases (PKSs) produce a wide range of
medically signi¢cant compounds. In the case of the pikromycin PKS of
Streptomyces venezuelae, four separate polypeptides (PikAI^PikAIV), comprising
a total of one loading domain and six extension modules, generate the 14-
membered ring macrolactone narbonolide. The polypeptide PikAIV contains a
thioesterase (TE) domain and is responsible for catalyzing both the last
elongation step with methylmalonyl CoA, and subsequent release of the ¢nal
polyketide chain elongation intermediate from the PKS. Under certain growth
conditions this polypeptide is synthesized from an alternative translational start
site, giving rise to an N-terminal truncated form of PikAIV, containing only half of
the ketosynthase (KS6) domain. The truncated form of PikAIV is unable to
catalyze the ¢nal elongation step, but is able to cleave a polyketide chain from the
preceding module on PikAIII (ACP5), giving rise to the 12-membered ring product
10-deoxymethynolide.
Results: S. venezuelae mutants expressing hybrid PikAIV polypeptides
containing acyl carrier protein (ACP) and malonyl CoA speci¢c acyltransferase
(AT) domains from the rapamycin PKS were unable to catalyze production of 12-
or 14-membered ring macrolactone products. Plasmid-based expression of a
hybrid PikAIV containing the native KS6 and TE domains, however, restored
production of both narbonolide and 10-deoxymethynolide in the S. venezuelae
AX912 mutant that generates a TE-deleted form of PikAIV. Use of alternative KS
domains or deletion of the KS6 domain within the hybrid PikAIV resulted in loss of
both products. Plasmid-based expression of a TE domain of PikAIV as a separate
polypeptide in the AX912 mutant resulted in greater than 50% restoration of 10-
deoxymethynolide, but not in mutants expressing a hybrid PikAIV bearing an
unnatural AT domain. Mutants expressing hybrid PikAIV polypeptides containing
the natural AT6 domains and different ACP domains ef¢ciently produced
polyketide products, but with a signi¢cantly higher 10-deoxymethynolide/
narbonolide ratio than observed with native PikAIV.
Conclusions: Dimerization of KS6 modules allows in vivo formation of a PKS
heterodimer using PikAIV polypeptides containing different AT and ACP domains.
In such heterodimers, the TE domain and the AT6 domain responsible for
formation of the narbonolide product are located on different polypeptide chains.
The AT6 domain of PikAIV plays an important role in facilitating TE-catalyzed
chain termination (10-deoxymethynolide formation) at the proceeding module in
PikAIII. The pikromycin PKS can tolerate the presence of multiple forms (active
and inactive) of PikAIV, and decreased ef¢ciency of elongation by PikAIV can
result in increased levels of 10-deoxymethynolide. These results provide new
insight into functional molecular interactions and interdomain recognition in
modular PKSs.
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Introduction
Modular polyketide synthases (PKSs) are responsible for
generating the macrolide core of a diverse range of poly-
ketide products with pharmaceutical, veterinary and agri-
cultural applications [1]. These PKSs are comprised of nu-
merous large multifunctional enzymes containing one or
more discrete modules that catalyze the successive conden-
sation of different extender units such as malonyl CoA and
methylmalonyl CoA onto a starter unit (Figure 1) [2]. Each
module contains an acyltransferase (AT) domain responsi-
ble for loading the appropriate extender unit onto an acyl
carrier protein (ACP) domain [2]. A ketosynthase (KS) do-
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main at the beginning of the module catalyzes a decarbox-
ylative condensation of this extender unit with a growing
polyketide chain obtained from a proceeding module and
generates an ACP-bound 3-ketoacyl product. The level of
3-keto group processing prior to the next chain extension
step is determined by the presence of ketoreductase (KR),
enoyl reductase (ER) and dehydratase (DH) domains with-
in the module [3]. A thioesterase (TE) domain attached to
the C-terminus of the last module is responsible for cleav-
ing the acyl chain from the adjacent ACP domain and is
presumed to catalyze cyclization to the macrolactone. The
modular nature of the PKSs makes them particularly ame-
nable to bioengineering approaches for designing catalysts
capable of generating novel polyketide structures [4]. A
number of hybrid and novel PKSs have been generated
with alterations to the PKS ranging from deletion/insertion
of domains and module switches and to combining com-
plete PKS polypeptides from different systems [4^6].
Figure 1. Biosynthesis of 10-deoxymethynolide and narbonolide by the pikromycin PKS (adapted from Xue and Sherman [12]). The
system is comprised of six modules for elongation and one loading module (module L). Catalytic domains with the modules of the PKS are
represented by circles (KS, ketosynthase; AT, acyl transferase; KR, ketoreductase; ACP, acyl carrier protein; DH, dehydratase, ER, enoyl
reductase; KSQ, a methylmalonyl decarboxylase; TE, thioesterase). Final products generated by the action of the desosamine biosynthetic
enzymes (Des) and a cytochrome P450 monoxygenase (PikC) are methymycin (R1, OH; R2, H), neomethymycin (R1, H; R2, OH),
pikromycin (R3, OH) and narbomycin (R3, H).
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Proteolytic analysis of the erythromycin PKS has shown
that the different multienzymes exist as parallel (possibly
helical) homodimeric complexes where identical modules
interact closely across the dimer interface [7]. This arrange-
ment allows identical modules to share active sites for
chain extension and possible chain termination. Mutagen-
esis studies with the erythromycin PKS have clearly dem-
onstrated that the KS domain within a module can interact
with the ACP on the complementary chain [7,8] and that
the AT domain can act on the ACP in either chain [9]. A
number of different models for the structure of PKSs have
been proposed based on these observations [8,10].
The pikromycin PKS of Streptomyces venezuelae has several
unique attributes, including the ability to generate both
12- and 14-membered ring macrolactone products under
different culture conditions [11]. This system generates a
hexaketide product by using three polypeptides, PikAI,
PikAII and PikAIII, to elongate a propionyl starter unit
through ¢ve elongation steps (Figure 1). In PGM media,
PikAIV containing just one module catalyzes an additional
elongation step using methylmalonyl CoA, and generates a
heptaketide product [12]. This product is then released
from PikAIV by a TE domain and cyclized to produce
narbonolide, which is subsequently converted to narbomy-
cin and pikromycin. In SCM media polyketide chain ex-
tension is terminated at the end of PikAIII to generate 10-
deoxymethynolide, which in turn is converted to methy-
mycin and neomethymycin [12]. In SGGP media a mixture
of both 12- and 14-membered ring macrolactone products
are formed. The premature chain termination is catalyzed
by the TE domain at the C-terminus of PikAIV [12]. It has
recently been shown that under these conditions an alter-
native translational start codon 600 nucleotides down-
stream of the normal pikAIV start codon is used, giving
rise to a N-terminal truncated PikAIV containing only
half of the KS6 domain and is unable catalyze the ¢nal
chain elongation step [12]. It has been proposed that par-
tial loss of this domain allows for a functional interaction
between the TE domain of the truncated PikAIV and the
hexaketide product bound to the ACP domain of PikAIII
(an interaction that is blocked when the complete KS6 is
present in PikAIV) (Figure 2) [12]. This unusual chain
termination mechanism generates multiple polyketide
products from a single PKS and represents a potentially
useful tool for combinatorial biosynthetic approaches for
generating libraries of new natural products. The unusual
nature of PikAIV to interact in two different forms in a
Figure 2. Proposed model for the role of
PikAIV in production of narbonolide (a) and
10-deoxymethynolide (b) (adapted from
Xue and Sherman [12]). Abbreviations for
the catalytic domains (depicted as
spheres) are provided in Fig. 1. Different
shades of blue indicate the two
polypeptide components of the homodimer.
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catalytically distinct manner with PikAIII also offers a
unique system for understanding the interactions and func-
tional orientations of domains within a PKS dimer, and the
interpolypeptide interactions that allow chain elongation
intermediates to be transferred to subsequent modules.
Here we describe the results of probing these interactions
in vivo using a range of hybrid PikAIV polypeptides.
Results and discussion
Expression of PikAIV and the TE domain as separate
polypeptides decrease narbonolide production but not
10-deoxymethynolide production
The mutant S. venezuelae AX912 in which both the TE
domain of PikAIV and the TEII had been deleted was
previously constructed, and has been shown to produce
no detectable polyketides under culture conditions for
10-deoxymethynolide (SCM media) or narbonolide pro-
duction (PGM media) [12]. Similarly, no products were
obtained in this current study when this strain was grown
in SGGP media, which allows for production of both 10-
deoxymethynolide and narbonolide (Table 1). A new strain
SC1022 with a complete pikAIV and an in-frame deletion of
pikAV (encoding TEII) was generated and shown to pro-
duce both of these aglycone products (Table 1), clearly
supporting the importance of the TE domain in termina-
tion of polyketide extension at both PikAIII and PikAIV.
No glycosylated products were formed because the dele-
tion of the pikAV encoding TEII affects expression of
downstream genes involved in desosamine biosynthesis
and transfer (Chen et al., unpublished results). Mutant
BL3001 [13] impaired in desosamine biosynthesis pro-
duced similar levels of aglycone products as observed for
the SC1022 strain (Table 1).
Table 1
Production of 10-deoxymethynolide and narbonolide in SGGP media by S. venezuelae strains producing either hybrid PikAIV poly-
peptides and/or PikAIV without a TE domain.
Natural PikAIV domains are shown in blue and the domains from the PKS module are shown in red (the same color schemes are used in
Figures 3 and 4). Brackets indicate the general area where fusion of the catalytic domains of the various PKSs occurred (a more detailed
description is provided in the text). The bracket in K[S and A[T indicate that the fusion point was made within the conserved catalytic do-
main. The dash between the different regions indicates the peptide linker region. The AT13, ACP13 and ACP14 are domains of RapC of the
rapamycin PKS. napATx -DHx -KRx -ACPx are from a module x of the putative naphthomycin PKS. tylAT7-KR7-ACP7-TE is a module from the
tylosin PKS. Yields were determined against a standard curve derived for both 10-deoxymethynolide and narbonolide. ND, not detectable.
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A series of complementation experiments was then carried
out using the AX912 strain. In these and subsequent com-
plementation studies plasmid-based expression was accom-
plished using a low copy plasmid [12] and the pikAI pro-
moter, PpikAI (allowing synchronized expression at similar
levels as other components of the pikA cluster). Plasmid-
based (pDHS707) expression of a complete PikAIV in the
AX912 strain also gave both aglycones in SGGP media
with overall lower yields (approximately 50%) and a sig-
ni¢cantly greater proportion of narbonolide relative to 10-
deoxymethynolide than seen with SC1022 (Table 1). A
similar increase in this ratio was observed when this strain
AX912/pDHS707 is grown in SCM media, which typically
produces predominantly 10-deoxymethynolide [12]. One
possible explanation for the observed increase in narbono-
lide relative to 10-deoxymethynolide is that such plasmid-
based expression of PikAIV may utilize the alternative
translational start site (giving rise to the N-terminal trun-
cated PikAIV) less readily as compared to chromosomal-
based expression. The lower overall polyketide yields
with the plasmid-based expression of PikAIV is presum-
ably a re£ection of the presence of the TE-deleted chro-
mosomal copy of PikAIV.
Plasmid-based (pDHS704) expression of TE in the AX912
strain gave an apparent complete restoration of 10-deoxy-
methynolide production and low levels of narbonolide pro-
duction (8%) as compared to the SC1022 strain. Similar
results have previously been seen for this strain grown in
SCM media (60% restoration of 10-deoxymethynolide) and
PGM media (no detectable narbonolide production). The
small variations in levels of antibiotic production (0% ver-
sus 8% for narbonolide production, for instance) presum-
ably re£ects the use of different media and the typical
£uctuations observed for experiments performed using sev-
eral randomly picked transformants. In all experiments the
low levels of narbonolide product (6 10%) are presumably
a result of a poor functional association between the ACP
domain of PikAIV and the TE, and is consistent with
previous analyses of erythromycin where the TE domain
functions ef¢ciently only when covalently linked to ACP
[14]. Conversely, substantial restoration of 10-deoxymeth-
yonlide production (60^100%) in all of these experiments
indicate that the TE domain is able to form a relatively
ef¢cient interaction with the PikAIII ACP5 when the trun-
cated form of PikAIV is present. This interaction appears
to be facilitated in part by the AT6 domain of PikAIV (see
below).
A TE domain attached to a functionally inactive hybrid
PikAIV releases narbonolide from a PikAIV module
lacking a terminal TE domain
A plasmid (pSC43) expressing a hybrid PikAIV polypep-
tide (KS6[-AT14-ACP14-]rapTE) comprised of the PikAIV
KS6, TE domains and the rapAT14-ACP14 domains from
RapsC of the rapamycin PKS [15] was constructed and
introduced into the AX912 strain. The rapAT14 domain is
responsible for incorporating a malonyl CoA extender unit
during rapamycin biosynthesis and would be predicted to
generate a 2-desmethylnarbonolide product when intro-
duced into PikAIV. No evidence of this compound could
be found suggesting that the hybrid PikAIV was unable to
extend the polyketide chain. A chromosomal mutant
(SC1017) containing only this hybrid PikAIV was gener-
ated and also shown to produce no detectable 14-mem-
bered ring macrolactone product, leading to the same con-
clusion (see below) (Table 1).
Plasmid-based (pSC43) expression of the hybrid PikAIV
(KS6[-AT14-ACP14-]rapTE) in the TE-deleted AX912 strain
did, however, produce narbonolide. No narbonolide was
observed in a control when this plasmid (pSC43) was ex-
pressed in SC017 (expressing the same hybrid PikAIV)
(Table 1). The level of production of this aglycone was
10-fold less than seen for plasmid-based (pDHS707) ex-
pression of native PikAIV. Production of narbonolide rather
than 2-desmethylnarbonolide and the dependence on the
presence of TE-deleted PikAIV is consistent with the
elongated polyketide chain being generated using the
AT6 domain on this C-terminal truncated PikAIV and
the TE module on the hybrid PKS (Figure 3A). Thus, it
seems likely that a heterodimeric polypeptide must form
consisting of this hybrid PikAIV and the TE-deleted
PikAIV (Figure 3A). The decrease in narbonolide produc-
tion relative to a control experiment using pDHS707 is
consistent with the proposal that only the heterodimeric
PikAIV complexes (which consists of one, rather than
two complete sets of catalytic activities) but neither of
the homodimeric complexes, can produce narbonolide
(Figure 3A).
Evidence for formation of heterodimeric PKSs have been
previously reported for the erythromycin and pikromycin
PKSs [8,12]. In these cases the two polypeptides either
differed in mutations in active site residues of speci¢c
domains, or contained speci¢c domain deletions. Studies
with the erythromycin heterodimers have clearly demon-
strated that the polyketide chain is transferred both within
and between the two polypeptide chains at different stages
as it is processed through the PKS [8,10]. These studies
have also shown that the AT domain can catalyze acylation
of the ACP domain on either subunit [9]. It is therefore
possible that the AT6 within the proposed PikAIV hetero-
dimer might function on both ACP6 and rapACP14 (Figure
3A). It remains to be determined which of these ACP
domains carries the fully elongated polyketide chain that
is cleaved by the TE.
Dimerization of KS6 domains is essential for formation of
a functional heterodimer between an inactive hybrid
PikAIV and a TE-truncated form of PikAIV
In the current study the proposed heterodimeric complex
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forms between signi¢cantly different polypeptides contain-
ing AT and ACP domains from different PKSs (Figure 3A).
Both polypeptides contain the PikAIV KS6 domain and the
importance of this in formation of the proposed heterodi-
meric PikAIV complex was probed through a series of
complementation experiments.
First, the KS6 domain from the hybrid PKS was removed.
A plasmid (pSC73) capable of expressing a polypeptide
([-AT14-ACP14-]rapTE) composed of the RapC AT14-ACP14
and the PikAIV TE domain was constructed. When this
plasmid was introduced into the AX912 strain, neither 10-
deoxymethynolide nor narbonolide were detected, sup-
porting the hypothesis that the proposed heterodimer can-
not form in the absence of KS6 (Table 1). In contrast, both
of these products have previously been observed with plas-
mid-based expression of AT6-ACP6-TE (pDHS708) in the
same AX912 strain [12], presumably because of a dimeri-
zation of the AT6-ACP6 domains. In the latter case it is
noted that the dimer contains only one KS domain which
must, therefore, be responsible for catalyzing the ¢nal
elongation step. This domain is located on the TE-deleted
form of PikAIV, while the TE responsible for catalyzing
narbolide formation is contained on the AT6-ACP6-TE
polypeptide chain.
Second, a plasmid (pSC51) capable of expressing a hybrid
PikAIV containing only the N-terminal region of PikAIV
(including the ¢rst 118 amino acids of KS6) and the TE
and a KS-AT-DH-ACP domain from a module of the pu-
tative Streptomyces collinus naphthomycin (nap) PKS [16]
was constructed. A second plasmid (pSC63) capable of ex-
pressing a hybrid PikAIV containing just the N-terminal
region of PikAIV (including the ¢rst 81 amino acids of
KS6) and the KS7-AT7-DH7-ACP7-TE domain of the mod-
ule 7 of the tylosin (tyl) PKS was prepared. Expression of
either pSC63 or pSC51 in the AX912 mutant failed to
produce detectable levels of narbonolide, 10-deoxymeth-
ynolide, or any other aglycone products under standard
fermentation conditions (Table 1). These observations sup-
port the hypothesis that formation of a heterodimer
capable of generating 10- or 12-membered ring macrolac-
tone products requires at least one domain such as KS6 to
be present on both polypeptide chains. Such a ¢nding
supports the proposed structural models for the erythromy-
cin PKS where the core structure is achieved by strong
association of KS domains [10]. We propose that the ap-
parent inability of different KS domains to form a func-
tional dimer may ensure that only homodimeric complexes
are formed in unmodi¢ed PKSs, thus maximizing the pro-
duction of a single polyketide product.
A TE-deleted PikAIV is required for a hybrid, functionally
inactive PikAIV containing a TE domain to release
10-deoxymethynolide products from PikAIII
Plasmid-based expression (pSC43) of the hybrid PikAIV in
AX912 gave approximately an eight-fold increase in the
levels of 10-deoxymethynolide as compared to plasmid-
based expression (pDHS707) of the wild-type PikAIV.
The TE attached to the hybrid PikAIV must terminate
polyketide chain extension at PikAIII. In contrast a
PikAIV chromosomal mutant (SC1017) containing only
this hybrid PikAIV was unable to generate 10-deoxymeth-
ynolide. Similarly no 10-deoxymethynolide was generated
when SC1017 was transformed with pSC43. These obser-
vations suggest that formation of a heterodimeric PikAIV
complex is also necessary for TE to act upon PikAIII. Only
the latter half of the KS6 can be used to form heterodimers
because the N-terminal region is not generated in the
truncated form of PikAIV that produces 10-deoxymethyno-
lide [12] (Figure 3B).
The observation that AX912/pSC43 strain can produce sig-
ni¢cant levels of 10-deoxymethynolide is surprising given
that the PikAIV homodimers generated in this system are
predicted to be inactive (Figure 3A,B). The SGGP media
allows production of both 10-deoxymethynolide and narbo-
nolide products and thus AX912/pSC43 presumably produ-
ces the hybrid PikAIV and wild-type PikAIV in both the
complete and N-terminally truncated form allowing six dif-
ferent PikAIV dimeric complexes to be present (Figure
3A,B). If the N-terminally truncated PikAIV and full
length PikAIV polypeptides can dimerize then as many
as 10 dimeric forms of PikAIV may be present, of which
only heterodimeric forms may be active. A static model for
the pikromycin PKS in which these different PikAIV poly-
peptides associate with PikAIII in vivo and do not readily
dissociate would give rise predominantly to inactive PKSs
not containing a TE domain, and signi¢cantly decreased
yields of both narbonolide and 10-deoxymethynolide. A
dynamic model in which the various forms of PikAIV rap-
idly temporarily associate and dissociate can also be envi-
sioned. In this model, PikAIII would associate with
PikAIV heterodimers capable of forming both narbonolide
and 10-deoxymethynolide. In such a model a dramatic de-
crease in narbonolide production due to the presence of
6
Figure 3. Proposed interaction of PikAIII with a heterodimer comprised of a TE-deleted PikAIV and a hybrid PikAIV. The AT14 and ACP14
domains of RapsC are shown in red, while the natural domains of the pikromycin PKS are shown in blue. This heterodimer expressed with
the complete (A) and truncated KS6 domain (B) is proposed to be responsible for generation of narbonolide and 10-deoxymethynolide,
respectively, in the AX912 strain carrying pSC43. Homodimers comprised solely of either the hybrid PikAIV, or the TE-deleted PikAIV, are
unable to generate either product (Table 1).
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mutant PikAIV polypeptides unable to elongate, could pro-
duce a concomitant increase in 10-deoxymethynolide. This
increase would occur so long as the heterodimers contain-
ing a truncated PikAIV polyketide are able to catalyze
chain termination at PikAIII. The overall suppression of
aglycone production in the AX912/pSC43 (33%) and
AX912/pDHS707 (50%), compared to the SC1022 control,
presumably re£ects a slowing of polyketide chain exten-
sion due to the temporary association of PikAIII with in-
active forms of PikAIV.
The PikAIV AT6 domain is essential for generating both
12- and 14-membered ring macrolactones
A series of different chromosomal mutants in the pikAIV
locus were constructed to investigate the reason why a
hybrid PikAIV, in which AT6-ACP6 had been replaced
with AT14-ACP14 of RapC, cannot produce either 10-de-
oxymethynolide, narbonolide or any other product. Strain
SC1017 that produced this hybrid PikAIV using a fusion
point that allows 35 amino acids of a unique linker region
upstream of AT14 of RapC [15] was generated (the same
fusion point was used for pSC43 plasmid-based expression
of this hybrid PikAIV). This KS14-AT14 linker of RapC,
based on published sequence pile-up data [14], was used
in place of normal PikAIV KS6-AT6 linker. Strain SC1020
produced a hybrid PikAIV with the AT6/rapAT14 fusion
point 22 amino acids into the conserved domain of AT6.
A similar fusion point using the rapAT14 (three amino acids
into a conserved AT domain) has previously been reported
in the successful generation of a hybrid erythromycin PKS
capable of producing a desmethyl 6-deoxyerythronolide B
analog [17]. Strain SC1021 contained a hybrid AT having
the N-terminal region of PikAIV AT6 and the C-terminal
region of rapAT14. The fusion point used to generate this
chimeric AT was in a highly conserved region that comes
25^35 amino acids after the proposed AT binding motifs
which specify malonyl CoA or methylmalonyl CoA specif-
icity [18]. The fusion juncture was, however, before the
recently described hypervariable region of the AT domain,
suggested to determine substrate speci¢city [19].
None of these mutants (SC1017, SC1020, SC1021) were
observed to generate detectable levels of either 10-deoxy-
methynolide or narbonolide (Figure 4). Only a mutant
(SC1016) expressing a hybrid PikAIV containing the entire
conserved AT6 domain (the fusion point in this mutant was
Figure 4. Production of narbonolide and 10-deoxymethynolide using pikromycin PKS in ¢ve S. venezuelae strains which produce different
hybrid PikAIV polypeptides. The rapamycin PKS domains from module 14 and 13 are shown in red. As all strains were grown in SGGP
media, the full length PikAIV products would be accompanied by N-terminal truncated PikAIV products (not depicted).
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made at the beginning of the linker region between AT6
and ACP6) produced 10-deoxymethynolide (Table 1 and
Figure 4). Even in this mutant no detectable levels of
narbonolide were generated. In terms of 10-deoxymeth-
ynolide production, these results indicate that the N-ter-
minal truncated hybrid PikAIV is unable to bring TE into
the appropriate position at the end of PikAIII, unless AT6
is present (an interaction is either facilitated by AT6, or
blocked by the presence of alternative AT domains).
This hypothesis was supported by the observation that
plasmid-based (pDHS704) expression of the TE domain
in SC1020 did not result in the production of 10-deoxy-
methynolide, even though signi¢cant levels (12 mg/l) were
observed when this complementation experiment was car-
ried out using the AX912 strain (Table 1). In the comple-
mentation studies when plasmid-based expression of a hy-
brid PikAIV with AT14 does produce 10-deoxymethynolide
(AX912/pSC43), the AT6 is presumably provided by di-
merization with the TE-deleted PikAIV. Thus, in all ex-
periments carried out in the absence of AT6, a TE domain
whether attached to a hybrid PikAIV, or expressed as a
separate polypeptide, cannot cleave polyketide products
from PikAIII.
Recent studies using the erythromycin PKS have sug-
gested that the N-terminal region upstream of a KS do-
main of an N-terminal module contains an ‘interpolypep-
tide linker’ which plays an important role in facilitating
transfer of an extended polyketide chain from the ACP
domain of the preceding polypeptide [20]. In the case
where the N-terminal region of PikAIV is deleted, such a
linker would be absent and thus one of the roles of AT6 in
the PikAIV may be to facilitate interaction with PikAIII.
This interaction may explain the surprising ef¢ciency of
10-deoxymethynolide production when TE is provided in
trans (pDHS704) to the AX912 strain (Table 1).
The lack of detectable narbonolide or 2-desmethylnarbo-
nolide production with mutants expressing PikAIV hybrids
with alterations in the AT and ACP domains is most likely
indicative of a catalytically inactive or inef¢cient module.
The fact that SC1016 expressing a hybrid PikAIV with
only ACP6 substitution can produce 10-deoxymethynolide
but not narbonolide, suggests that at least in this case an
association of the PikAIII and hybrid PikAIV polypeptides
is possible. It is now well established that using gene fu-
sion approaches to create hybrid PKSs with domain sub-
stitutions often leads to decreased in vivo productivity
[5,21]. Suggested reasons for the lower productivity in-
clude suboptimal catalysis within the altered PKS, struc-
tural instability of the hybrid protein, or inef¢cient process-
ing of the nonnatural polyketide intermediate by
downstream modules [20]. Some of the nonproductive
changes in PikAIV (SC1016) should not in principle affect
the ¢nal product structure, and the TE domains in many
of the PikAIV hybrids can release products from either
PikAIII, or PikAIV in the proposed heterodimers. Presum-
ably then, most hybrid PikAIV homodimers are unable to
produce signi¢cant levels of the predicted 14-membered
ring macrolactone due to inef¢cient catalysis.
Hybrid PikAIV polypeptides containing different ACPs
produce different ratios of 12- and 14-membered ring
macrolactones
Only one hybrid PikAIV, in which the ACP6 was replaced
by the rapACP13 was able to generate signi¢cant levels of
the 14-membered ring narbonolide product (SC1015). The
reason why a hybrid PikAIV containing the rapACP13
(SC1015) and not the rapACP14 (SC1016) can catalyze elon-
gation is unclear, but may re£ect the difference in linker
regions £anking the two ACPs. The rapACP14 switch in-
cluded the 15 amino acid linker region between rapAT14
and rapACP14 of RapsC, while the rapACP13 switch in-
cluded the 35 amino acid linker region between rapKR13
and rapACP13 of RapsC [15]. The ACP13 switch was linked
to TE using the amino acid region between rapACP13 and
rapKS14, while a similar fusion using ACP14 involved the
unusual C-terminal region of RapsC (a region that might
be involved in forming an interaction with RapP, the pro-
tein involved in termination of rapamycin polyketide chain
extension).
Even though strain SC1015 produces narbonolide, in vivo
production is only approximately 30% of that observed for
the control strain (SC1022) expressing the wild-type
PikAIV. Thus, the hybrid PikAIV with the rapACP13 is still
less ef¢cient at elongation. This strain, grown in SGGP
media, however, produced the highest levels of 10-deoxy-
methynolide (four-fold higher than the SC1022 control) out
of all experiments performed. Interpreting this data from a
static model for polyketide production in which the full
length and N-terminal truncated forms of PikAIV are
used to form distinct pikromycin PKSs (Figure 2) would
require that (a) the hybrid PikAIV is less ef¢cient at elon-
gation yet more ef¢cient at chain termination at PikAIII,
and (b) that chain termination in both forms is rate-limit-
ing. As described above, a dynamic model in which these
two forms rapidly associate and dissociate from PikAIII
must be considered. In such a model a hybrid PikAIV
less ef¢cient at chain elongation would decrease narbono-
lide production and provide greater opportunities for the
truncated PikAIV to terminate elongation at PikAIII, thus
increasing 10-deoxymethynolide production.
Signi¢cance
Modular PKSs are large multifunctional enzymes contain-
ing discrete modules, responsible for elongating small car-
boxylic acid precursors into complex polyketide products
via a sequential process. The individual polypeptide com-
ponents of bacterial type I PKS systems contain one or
more dimerized modules. The interactions between the
dimers, and the manner in which the different polypeptide
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components interact are important factors that allow the
molecular assembly line process to typically generate one
aglycone product. The generation of novel polyketides
through rational bioengineering of these PKS systems
will be aided by understanding these processes and how
they can be altered.
The pikromycin PKS produces ketolide antibiotics, a class
of natural products that have recently attracted signi¢cant
interest because of their activity against a number of mac-
rolide-resistant microorganisms [22]. The last polypeptide
(PikAIV) of this PKS generates the ketolide functionality
in 14-membered ring macrolactone products, and also plays
a role in producing 12-membered ring macrolactones by
terminating chain extension at the C-terminus of PikAIII.
We have provided strong evidence that the AT6 domain
within PikAIV plays an important role in facilitating TE-
catalyzed chain termination at ACP5 of PikAIII. In addi-
tion, these studies show for the ¢rst time that in vivo PKS
heterodimer complexes can be formed using modules that
share only a KS domain in common. In such a heterodimer,
the TE domain responsible for terminating polyketide
chain extension and the AT domain responsible for loading
the methylmalonyl CoA extender unit are apparently lo-
cated on separate polypeptides. Finally, we have shown
that the pikromycin PKS can tolerate the presence of mul-
tiple forms (active and inactive) of PikAIV, the polypeptide
catalyzing the ¢nal elongation step in pikromycin. This
observation suggests that there is a dynamic interaction
between PikAIV and the PikAIII polypeptide responsible
for catalyzing the preceding chain elongation step. These
¢ndings may be useful in various combinatorial biosyn-
thetic applications, such as the generation of a range of
polyketide products from a single recombinant microorgan-
ism.
Materials and methods
Bacterial strains and culture conditions
The mutant AX912 was previously created by targeted gene replace-
ment with wild-type S. venezuelae ATCC 15439 [12]. All the subsequent
mutants substituted at AT6 and/or ACP6 domains on chromosome were
obtained from AX912 by standard homologous recombination proce-
dures. AX912 was also used as the host for the production of polyke-
tides from the engineered plasmids derived from pAX702. Escherichia
coli TG1 (Stratagene) was used throughout this study as a cloning host,
growing in standard culture conditions. S. venezuelae strains were
grown on R2YE agar plates after transformation and then transferred
to sporulation agar for production of spores. SGGP liquid medium was
used for propagation of S. venezuelae mycelia and antibiotic production
[23].
Manipulation of DNA and organisms
The manipulation and transformation of DNA in E. coli was performed by
general molecular cloning procedures. Polymerase chain reaction (PCR)
was performed with rTth enzyme (Perkin-Elmer) under conditions rec-
ommended by the manufacturer. S. venezuelae were transformed by
standard procedure and transformants were selected on agar plates
using thiostrepton and/or apramycin (50 Wg/ml).
PCR ampli¢cation of DNA fragments
DNA fragments used for constructing the various recombination and
expression plasmids were PCR ampli¢ed from plasmids or cosmids
containing pikAIV (pDHS707, cosLZ51) [12], rapsC (cos2, cos8, cos9,
provided by Leonard Katz, Abbott Laboratories), tylG (pOJ566, a gift
from Eli Lilly Co.) and the gene encoding a module from the putative
naphthomycin PKS (cos7G11) [16]. The following oligonucleotides with
designed restriction sites (italics) for ligation were used (all shown as
5PC3P): A 960 bp NdeI^BamHI fragment containing 3P region of pikAIV
(encoding the TE domain), forward GGCGGAGGAGCATATGGAAGAA-
GATCCGGC and reverse GCGCCGGATCCACAGTCCGCTGTCCAC; a
1.32 kb EcoRI^NdeI/XbaI fragment containing the internal region of
pikAIV encoding the AT6-ACP6 (for pSC992 construction), forward
CCCGAATTCGCCGCCGCCATGGCCGAAT (EcoRI) (primer 1) and re-
verse GACGGCTCTAGACGGCCCATATGCGCTCGGCC (NdeI/XbaI); a
1.75 kb XbaI fragment containing pikAV and desVIII region and the 3P
region of pikAIV (for pSC992 construction), forward GGCTCTAGATCG-
ATGGCATCGAGGGGGCGGGCAAGTGACCGACA and reverse GGG-
TCTAGAGCTGCACCGGCGGGTCGTAGCGGA; a 1 kb EcoRI^XhoI
fragment containing a region of pikAIV encoding AT6 (for pSC1002
and pSC1003 construction), primer 1 (forward) and reverse GGCGAC-
GGCCTCGAGCCCGGAAGCGGTG; a 420 bp XhoI^NdeI fragment
(fragment A) containing a region of rapsC encoding ACP13 (for
pSC1015 construction), forward TGCGCGGACTCGAGACGGTGAAG-
CGTCC and reverse GGCGATCGGCATATGCGCCGACGGCTCA; a
480 bp XhoI^NdeI fragment (fragment B) containing a region of rapsC
encoding ACP14 (for pSC1016 construction), forward CTACTGGCTC-
GAGCCGGCCGCCCCGGAT and reverse CGTGTGACACCCATATGT-
TCGTTCCTGGTCC (primer 2); a 1.4 kb EcoRI^NdeI fragment encoding
the region of rapsC encoding AT14-ACP14 (for pSC1020 construction),
pSC1020 forward AGCTACCCCGAATTCGCACGTGCCTGGGAG
(EcoRI), and primer 2 (reverse); a 1.06 kb HindIII^NdeI fragment of
rapsC encoding the rapAT14-ACP14 region (for pSC1019 construction),
forward GGTGAGGAAGCTTTGAGGGAGTTCCTCAGC (HindIII) and
primer 2 (reverse); a 330 bp EcoRI^HindIII fragment of pikAIV encoding
the AT6-ACP6 region (for pSC1019 construction), primer 1 (forward),
and reverse GCTGCCGGGAAGCTTCCTCGCTGAGGGC (HindIII); a
1.6 kb BamH1^NdeI fragment (fragment C) of rapC encoding the
AT14-ACP14 region (for pSC1017 and pSC43 construction), forward
TCGCGGTGGGATCCGGGCCGGGAGGACT and primer 2 (reverse);
a 1.6 kb BamHI^NdeI/BamHI fragment containing the same region of
rapC as fragment C, using the same forward primer and reverse
CGCGGATCCATATGCCTCTCCATTCGTTCCTGGTCCTCCATTTT; a
BamHI^NdeI fragment (fragment D) of the same region of rapsC encod-
ing AT14-ACP14 (for pSC73 construction), forward TCGCGGTGGGAT-
CCGCCGGGAGGACT and primer 2 (reverse); A 410 bp EcoRI^NcoI
fragment of pikAIV encoding the RBS site and ¢rst 120 amino acids of
KS6 (for pSC51 construction), forward AGTGAGTCCGAGGAATTCATC-
GAGGGG (primer 3) and reverse AACAGGATCCGCTGCTGCGGGTC-
CATGGCCACCGCCTC; a 320 bp EcoRI^BamHI fragment of pikAIV
encoding the RBS site and ¢rst 80 amino acids of KS6 (for pSC63
construction), primer 3 (forward), reverse TTGCGCCCGGGATCCGGG-
TCGTAGAGC; a 5.1 kb NcoI^NdeI fragment from cos7G11 encoding
KS-DH-AT-ACP domains of a putative naphthomycin PKS module from
S. collinus (for pSC51 construction), forward AGGCGGTGGCCATGGA-
CCCGCAGCAG and reverse GATGGGATCCATTTCCATATGCACGG-
CCACCCCGGAGAGAC.
Construction of homologous recombination plasmids
pSC992 was obtained by ¢rst ligating the EcoRI^NdeI/XbaI PCR frag-
ment into pUC119. A XbaI fragment was then cloned into the XbaI site.
Two EcoRI^NdeI fragments were generated by ligating a EcoRI^XhoI
PCR fragment and the two XhoI^NdeI PCR fragments (fragments B and
C) and used to replace the corresponding region of pSC922 to generate
pSC1002 and pSC1003, respectively. The NdeI^BamHI PCR fragment
was then cloned into pSC1002 and pSC1003 that had been digested
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with NdeI^BglII. Subsequently, the EcoRI^XbaI fragments from these
pSC1002 and pSC1003 derivatives were cloned into pKC1139 and
made pSC1015 and pSC1016. A coligation of a natural 2.4 kb EcoRI^
BamHI fragment of pikAIV (encoding AT6-ACP6-TE, and the ¢rst 13
amino acids of TEII), with a 1 kb BglII^XbaI fragment of pSC992 pro-
duced an EcoRI^XbaI fragment that was cloned into pKC1139 to give
pSC1022. A 1.6 kb EcoRI^BamHI fragment (containing the region of
pikAIV encoding KS6) from pDHS707 was ligated with the BamHI^
NdeI PCR fragment (fragment C) and subsequently used to replace
the corresponding EcoRI^NdeI fragment in pSC1015, to generate
pSC1017. A 1.8 kb EcoRI fragment from pSC43 (see below) was ligated
with the EcoRI^NdeI PCR fragment and subsequently used to replace
the corresponding EcoRI^NdeI fragment in pSC1015, to generate
pSC1020. The PCR HindIII^NdeI fragment was ligated with the
EcoRI^HindIII fragment and subsequently used to replace the corre-
sponding EcoRI^NdeI fragment in pSC1016 to generate pSC1019.
The 1.8 kb EcoRI fragment from pSC43 was then cloned into the cor-
responding site in pSC1019 to generate pSC1021. The plasmids
pSC1015^1017 and pSC1020^1022 were used to generate the corre-
sponding S. venezuelae mutant, as described above.
Construction of expression plasmids
All the expression plasmids were derivatives of pDHS702 [12] a shuttle
vector, with an E. coli colE origin and a low copy Streptomyces origin
(based on SCP2*). Antibiotic selection for pDHS702 is provided by thio-
strepton in Streptomyces and ampicillin in E. coli. The expressed
genes are under the control of pikAI promotor, PpikAI. Plasmid
pDHS707 was digested with NdeI and religated after end-¢lling to obtain
pSC39. The 1.6 kb PCR BamHI^NdeI/BamHI PCR fragment was cloned
into the BamHI site of pSC39 to give pSC40. The NdeI^BamHI PCR
fragment was used to replace the NdeI^BglII fragment of pSC40 to give
pSC43. pDHS702 [12] was digested with NdeI and religated after end-
¢lling to obtain pSC38. The BamHI^NdeI PCR fragment (fragment D)
was ligated with the NdeI^BamHI PCR fragment and subsequently used
to replace the BamHI^BglII fragment of pSC38 to generate pSC73. The
EcoRI^NcoI PCR fragment was ligated with the NcoI^NdeI PCR frag-
ment and then used to replace the EcoRI^NdeI fragment of pSC43 to
create pSC51. The EcoRI^BamHI PCR fragment was ligated with a
natural 8.07 kb BamHI^NsiI fragment from pOJ566 (encoding almost
the entire tylosin module 7) and then cloned into the corresponding sites
of pSC38 to generate pSC63.
Puri¢cation and characterization of polyketide
Innoculated SGGP liquid media were incubated in a 30³C shaker for
3 days and 10-deoxymethynolide, narbonolide and related compounds
were extracted following published procedures [24]. Thin layer chroma-
tography (CHCl3:MeOH, 9:1) was routinely used to detect the antibiot-
ics. Further puri¢cation was conducted using £ash column chromatog-
raphy (CHCl3:MeOH, 9:1) and HPLC (MeCN:H2O, 50:50). Crude
extracts and puri¢ed compounds were analyzed by LC-MS.
Quanti¢cation of polyketide production
HPLC-puri¢ed 10-deoxymethynolide and narbonolide were dissolved in
MeOH and the absorbancy measured at UV 226 and 228.5 nm, respec-
tively. The concentration of the solutions was then calculated using the
known narbonolide (A, 8200) and 10-deoxymethynolide (A, 9100) molar
extinction coef¢cients [24,25]. Samples were then dried and serially
diluted with acetonitrile (MeCN). The dilutions were injected onto a
C18 reverse phase HPLC analytical column and eluted with 50:50
MeCN:H2O and the aglycones were detected by absorbance at 230
nm. Peak areas were integrated and plotted against the injected amount
of pure aglycone to obtain a standard curve. This was used subse-
quently to evaluate aglycone production in S. venezuelae. Antibiotic
production was averaged from at least three separate fermentations
with two selected colonies. In plasmid-based complementation, fresh
transformed colonies were used for inoculating a production culture.
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